Beijing Kawin Technology Share-holding Co Ltd
SSE:688687
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
22.5
38.59
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Beijing Kawin Technology Share-holding Co Ltd
Revenue
Beijing Kawin Technology Share-holding Co Ltd
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Beijing Kawin Technology Share-holding Co Ltd
SSE:688687
|
Revenue
¥1.2B
|
CAGR 3-Years
2%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
|
Beigene Ltd
HKEX:6160
|
Revenue
¥27.2B
|
CAGR 3-Years
53%
|
CAGR 5-Years
56%
|
CAGR 10-Years
N/A
|
|
|
Innovent Biologics Inc
HKEX:1801
|
Revenue
¥11.4B
|
CAGR 3-Years
36%
|
CAGR 5-Years
47%
|
CAGR 10-Years
N/A
|
|
|
RemeGen Co Ltd
SSE:688331
|
Revenue
¥1.7B
|
CAGR 3-Years
6%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Akeso Inc
HKEX:9926
|
Revenue
¥2.1B
|
CAGR 3-Years
111%
|
CAGR 5-Years
97%
|
CAGR 10-Years
N/A
|
|
|
S
|
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
HKEX:6990
|
Revenue
¥1.9B
|
CAGR 3-Years
291%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Beijing Kawin Technology Share-holding Co Ltd
Glance View
Beijing Kawin Technology Share-Holding Co., Ltd. provides biotechnology treatment solutions and medicines. The company is headquartered in Beijing, Beijing and currently employs 647 full-time employees. The company went IPO on 2021-02-08. The firm's recombinant human interferon α2b and compound glycyrrhizin drugs are applied to treat viral diseases. The firm mainly distributes its products within domestic market.
See Also
What is Beijing Kawin Technology Share-holding Co Ltd's Revenue?
Revenue
1.2B
CNY
Based on the financial report for Dec 31, 2024, Beijing Kawin Technology Share-holding Co Ltd's Revenue amounts to 1.2B CNY.
What is Beijing Kawin Technology Share-holding Co Ltd's Revenue growth rate?
Revenue CAGR 5Y
8%
Over the last year, the Revenue growth was -13%. The average annual Revenue growth rates for Beijing Kawin Technology Share-holding Co Ltd have been 2% over the past three years , 8% over the past five years .